REAL-LIFE COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER IMATINIB FAILURE FOR CHRONIC PHASE CML

被引：0

作者：

Tiribelli, M. ^{[1
]}

Bonifacio, M. ^{[2
]}

Binotto, G. ^{[3
]}

Iurlo, A. ^{[4
,5
]}

Cibien, F. ^{[6
]}

Maino, E. ^{[7
]}

Guella, A. ^{[8
]}

Festini, G. ^{[9
]}

Minotto, C. ^{[10
]}

De Biasi, E. ^{[11
]}

De Marchi, F. ^{[12
]}

Scaffidi, L. ^{[2
]}

Frison, L. ^{[13
]}

Bucelli, C. ^{[4
,5
]}

Medeot, M. ^{[1
]}

Calistri, E. ^{[14
]}

Sancetta, R. ^{[7
]}

Stulle, M. ^{[9
]}

Krampera, M. ^{[2
]}

Gherlinzoni, F. ^{[15
]}

Semenzato, G. ^{[3
]}

Ambrosetti, A. ^{[2
]}

Fanin, R. ^{[1
]}

机构：

[1] Azienda Osped Univ Udine, Div Hematol & BMT, Udine, Italy

[2] Univ Verona, Sect Hematol, Dept Med, Verona, Italy

[3] Univ Padua, Hematol Sect, Dept Med, Sch Med, Padua, Italy

[4] IRCCS Ca Granda Maggiore Policlin Hosp Fdn, Oncohematol Div, Milan, Italy

[5] Univ Milan, Milan, Italy

[6] Ca Foncello Hosp, Hematol Unit, Treviso, Italy

[7] DellAngelo Hosp, Hematol Unit, Venice, Italy

[8] Santa Chiara Hosp, Hematol Unit, Trento, Italy

[9] AOU Ospedali Riuniti, Div Clin Hematol, Trieste, Italy

[10] ULSS 13, Dept Med Special, Oncol & Oncohematol Unit, Venice, Italy

[11] P Cosma Hosp, Hematol Unit, Padua, Italy

[12] Azienda Osped Univ Udine, Div Hematol & BMT, Udine, Italy

[13] HemPadua Univ, Sch Med, Dept Med, Dept Med,Hematol Sect, Padua, Italy

[14] Ca Foncello Hosp, Hematol Unit, Treviso, Italy

[15] Ca Foncello Hosp, Hematol Unit, Treviso, Italy

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P612

引用

页码：237 / 238

页数：2

共 50 条

[1] Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients
Scalzulli, Emilia
Caocci, Giovanni
Efficace, Fabio
Rizzo, Lorenzo
Colafigli, Gioia
Di Prima, Alessio
Pepe, Sara
Fegatelli, Danilo Alunni
Carmosino, Ida
Diverio, Daniela
Latagliata, Roberto
La Nasa, Giorgio
Martelli, Maurizio
Foa, Robin
Breccia, Massimo
ANNALS OF HEMATOLOGY, 2021, 100 (05) : 1213 - 1219
[2] Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients
Emilia Scalzulli
Giovanni Caocci
Fabio Efficace
Lorenzo Rizzo
Gioia Colafigli
Alessio Di Prima
Sara Pepe
Danilo Alunni Fegatelli
Ida Carmosino
Daniela Diverio
Roberto Latagliata
Giorgio La Nasa
Maurizio Martelli
Robin Foà
Massimo Breccia
Annals of Hematology, 2021, 100 : 1213 - 1219
[3] Similar Efficacy of Dasatinib and Nilotinib As Second-Line Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Failing Imatinib: A Retrospective, Real-Life Study
Tiribelli, Mario
Bonifacio, Massimiliano
Binotto, Gianni
Iurlo, Alessandra
Cibien, Francesca
Maino, Elena
Guella, Anna
Festini, Gianluca
Minotto, Claudia
De Biasi, Ercole
De Marchi, Federico
Scaffidi, Luigi
Frison, Luca
Bucelli, Cristina
Medeot, Marta
Calistri, Elisabetta
Krampera, Mauro
Gherlinzoni, Filippo
Semenzato, Gianpietro
Ambrosetti, Achille
Pizzolo, Giovanni
Fanin, Renato
BLOOD, 2016, 128 (22)
[4] COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER INATINIB FAILURE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS
Tiribelli, M.
Bonifacio, M.
Binotto, G.
Maino, E.
Calistri, E.
De Marchi, F.
Scaffidi, L.
Frison, L.
Medeot, M.
Ambrosetti, A.
Semenzato, G.
Fanin, R.
HAEMATOLOGICA, 2015, 100 : 132 - 132
[5] Comparison of Treatment Changes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched From Imatinib to Nilotinib or Dasatinib As Second-Line Therapy
Macalalad, Alexander R.
Chen, Lei
Guerin, Annie
Luo, Jiayuan
Wu, Eric Qiong
Griffin, James D.
BLOOD, 2012, 120 (21)
[6] MDR1 expression predicts outcome of Ph plus chronic phase CML patients on second-line nilotinib therapy after imatinib failure
Agrawal, M.
Hanfstein, B.
Erben, P.
Wolf, D.
Ernst, T.
Fabarius, A.
Saussele, S.
Purkayastha, D.
Woodman, R. C.
Hofmann, W-K
Hehlmann, R.
Hochhaus, A.
Mueller, M. C.
LEUKEMIA, 2014, 28 (07) : 1478 - 1485
[7] MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure
M Agrawal
B Hanfstein
P Erben
D Wolf
T Ernst
A Fabarius
S Saussele
D Purkayastha
R C Woodman
W-K Hofmann
R Hehlmann
A Hochhaus
M C Müller
Leukemia, 2014, 28 : 1478 - 1485
[8] Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib
Khoury, H. Jean
Kim, Dong-Wook
Zaritskey, Andrey
Gambacorti-Passerini, Carlo
Hochhaus, Andreas
Navarro, Juan
Rapoport, Aaron P.
Dorlhiac-Llacer, Pedro Enrique
Zanichelli, Maria
Kelly, Virginia
Besson, Nadine
McMullan, Trevor
Kantarjian, Hagop M.
Cortes, Jorge E.
BLOOD, 2010, 116 (21) : 391 - 391
[9] Characteristics of Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy
Macalalad, Alexander R.
Chen, Lei
Guerin, Annie
Luo, Jiayuan
Wu, Eric Qiong
Griffin, James D.
BLOOD, 2012, 120 (21)
[10] Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
Khoury, H. Jean
Cortes, Jorge E.
Kantarjian, Hagop M.
Gambacorti-Passerini, Carlo
Baccarani, Michele
Kim, Dong-Wook
Zaritskey, Andrey
Countouriotis, Athena
Besson, Nadine
Leip, Eric
Kelly, Virginia
Bruemmendorf, Tim H.
BLOOD, 2012, 119 (15) : 3403 - 3412

← 1 2 3 4 5 →